Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMethodist Health System
About this trial
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
Eligibility criteria
Qualifiers
> 18 years of age
Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria.
Metastatic or Locally Advanced AND Inoperable
Clear disease progression on Octreotide over less than 3 years (RECIST 1.1)
Disqualifiers
Do not meet the Study Inclusion Criteria laid out in section 6.3
Trial design
Treatments tested in this trial
- Peptide Receptor Radionuclide Therapy
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov